Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Through the neoadjuvant treatment with a combination of Pucotenlimab and Lenvatinib, it
eventually enables the successful and safe implementation of partial nephrectomy in patients
with localized renal cancer, who have indications for nephron-sparing surgery but face
significant difficulty in kidney preservation (T1b with an endophytic component ≥75% or T2).